114,182 Shares in Henry Schein, Inc. $HSIC Acquired by WINTON GROUP Ltd

WINTON GROUP Ltd acquired a new stake in Henry Schein, Inc. (NASDAQ:HSIC) in the 3rd quarter, Holdings Channel reports. The firm acquired 114,182 shares of the company’s stock, valued at approximately $7,578,000.

Other institutional investors also recently bought and sold shares of the company. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein in the second quarter valued at $25,000. MUFG Securities EMEA plc acquired a new position in shares of Henry Schein during the 2nd quarter worth $27,000. Sentry Investment Management LLC raised its stake in shares of Henry Schein by 132.1% during the 3rd quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock worth $59,000 after buying an additional 515 shares during the last quarter. Evelyn Partners Investment Management Services Ltd purchased a new stake in shares of Henry Schein in the 2nd quarter worth about $62,000. Finally, Mather Group LLC. acquired a new stake in Henry Schein in the 3rd quarter valued at about $71,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Price Performance

NASDAQ:HSIC opened at $77.60 on Monday. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $89.29. The firm has a market cap of $8.90 billion, a price-to-earnings ratio of 23.73, a price-to-earnings-growth ratio of 2.30 and a beta of 0.87. The company’s 50-day moving average is $78.20 and its two-hundred day moving average is $72.63. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. The business had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Insiders Place Their Bets

In other news, Director Philip A. Laskawy sold 2,844 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $80.36, for a total transaction of $228,543.84. Following the sale, the director owned 21,961 shares in the company, valued at $1,764,785.96. This trade represents a 11.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Mark E. Mlotek sold 5,925 shares of Henry Schein stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total value of $478,740.00. Following the completion of the sale, the executive vice president directly owned 80,554 shares of the company’s stock, valued at approximately $6,508,763.20. This represents a 6.85% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 101,712 shares of company stock valued at $8,251,789. Company insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Henry Schein from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Leerink Partners increased their price target on shares of Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a research report on Tuesday, February 24th. Barclays started coverage on shares of Henry Schein in a research note on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective for the company. Morgan Stanley lifted their price objective on Henry Schein from $58.00 to $61.00 and gave the stock an “underweight” rating in a research report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. increased their target price on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $85.58.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.